Volex (AIM: VLX) upgrades FY2026 revenue to at least $1.22bn as AI data centre demand doubles and board eyes Main Market move
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 3 minute read Pharma Industry News Silexion Therapeutics’ SIL-204 shows promise in transforming pancreatic cancer treatment Silexion Therapeutics, a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies, has released compelling preclinical data for its… byPallavi MadhirajuJanuary 16, 2025